Wednesday, September 20, 2017 10:19:10 AM
We hold both JNJ and PFE in our portfolios.
DJ Pfizer Files Antitrust Lawsuit Alleging J&J Thwarted Use of Biosimilar Rival to Remicade
By Jonathan D. Rockoff
Pfizer Inc. filed suit against Johnson & Johnson on Wednesday, alleging it has thwarted biosimilar competition to its arthritis drug Remicade by effectively preventing health insurers, hospitals and clinics from offering Pfizer's lower-priced copy.
The complaint, filed in federal court in Philadelphia, says J&J's "exclusionary contracts" have stopped hospitals and clinics from buying Pfizer's Inflectra biosimilar and health insurers from paying for prescriptions if they wanted rebates and other perks.
Pfizer has asked the federal district court to void the contracts and order J&J to pay damages compensating for lost sales.
The lawsuit is the first antitrust action to surface in the emerging market for biosimilars, after years of litigation over patents and timing of launches.
Biotech drugs, which are produced in living cells and typically infused or injected, have provided help to patients with conditions ranging from cancer to hepatitis C to multiple sclerosis. But they cost a lot, often more than $100,000 a year for a patient.
The 2010 health-care overhaul aimed to limit spending on drugs whose patents had expired by creating a regulatory framework for the approval of copies. Last April, Inflectra was among the first biosimilars to get the go-ahead. Pfizer began selling it at the end of the year.
A year's treatment on Remicade typically lists for $31,500, nearly $6,000 more than for Inflectra, according to SSR Health.
Write to Jonathan D. Rockoff at Jonathan.Rockoff@wsj.com
(END) Dow Jones Newswires
September 20, 2017 09:11 ET (13:11 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Recent PFE News
- Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union • Business Wire • 09/20/2024 12:11:00 PM
- Targeting Cancer's Achilles Heel: AI-Driven DDR Therapies Offer Hope • AllPennyStocks.com • 09/17/2024 09:01:00 PM
- Pfizer Invites Public to View and Listen to Webcast of October 29 Conference Call with Analysts • Business Wire • 09/17/2024 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/16/2024 05:12:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/16/2024 05:11:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/16/2024 05:06:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/16/2024 05:04:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/16/2024 04:57:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/16/2024 04:56:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/16/2024 04:54:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/16/2024 04:53:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/16/2024 04:52:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/16/2024 04:47:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/16/2024 04:45:23 PM
- Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia • Business Wire • 09/14/2024 12:45:00 PM
- Pfizer’s BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer • Business Wire • 09/14/2024 08:15:00 AM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 09/13/2024 08:49:43 PM
- Pfizer Highlights Diverse Oncology Portfolio and Combination Approaches at ESMO 2024 • Business Wire • 09/11/2024 10:45:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 10:10:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 10:05:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 10:05:28 PM
- Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference • Business Wire • 08/28/2024 02:00:00 PM
- Pfizer Launches PfizerForAll™, a Digital Platform that Helps Simplify Access to Healthcare • Business Wire • 08/27/2024 10:45:00 AM
- Cruise and Uber Join Forces for Robotaxis, Alibaba Shifts Primary Listing to Hong Kong, Altria Hikes Dividend 4.1% • IH Market News • 08/23/2024 12:20:26 PM
- Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine • Business Wire • 08/22/2024 06:15:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM